Carfilzomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma: Final results from the NCI phase 2 pilot study Meeting Abstract
| Authors: | Landgren, O.; Roschewski, M.; Mailankody, S.; Kwok, M.; Manasanch, E. E.; Bhutani, M.; Tageja, N.; Kazandjian, D.; Zingone, A.; Costello, R.; Burton, D.; Zhang, Y.; Wu, P.; Carter, G.; Mulquin, M.; Zuchlinski, D.; Carpenter, A.; Gounden, V.; Morrison, C.; Maric, I.; Calvo, K. R.; Braylan, R. C.; Yuan, C.; Stetler-Stevenson, M.; Arthur, D. C.; Lindenberg, L.; Karen, K.; Choyke, P.; Steinberg, S. M.; Figg, W. D.; Korde, N. |
| Abstract Title: | Carfilzomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma: Final results from the NCI phase 2 pilot study |
| Meeting Title: | 56th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 124 |
| Issue: | 21 |
| Meeting Dates: | 2014 Dec 6-9 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2014-12-06 |
| Language: | English |
| ACCESSION: | WOS:000349243501164 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V124.21.4746.4746 |
| Notes: | Meeting Abstract: 4746 -- 56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CA -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
